Eastland enters malaria drug market through new deals

By Emilie Reymond

- Last updated on GMT

Related tags Malaria Africa

Australian contract manufacturing organisation (CMO) Eastland
Medical Systems has bagged a manufacturing and distribution
contract with UK's Proto-Pharma for its anti-malaria treatment.

This latest deal is part of Eastland's strategy to build a strong position within the anti-malaria treatment arena by accessing international markets through partnerships. Under the agreement, Eastland will manufacture and distribute commercial supplies of Proto-Pharma's new drug to Asia, India and the Pacific region. Cinical trials of the drug will begin in Malaysia within three months although Eastland will not be manufacturing the clinical supplies - they will be provided by Proto-Pharma. At this stage the company has the "know-how" but not the capacity for the manufacturing process of the drug but is now in the process of gaining the capabilities, Dermot Patterson, Eastland's CEO, told Outsourcing-Pharma.com. "There is no requirement in the short term for Eastland to have to produce the product during the clinical trial and regulatory approval process, so we will have time to gear up for the commercial production."​ However, the bulk of the manufacturing may not be carried out from Eastland's existing facilities in Australia. The firm is considering purchasing a new facility in the Asia-Pacific or Europe or outsourcing some of the manufacturing to a CMO in these regions, said Patterson. "Eastland islooking at a whole range of different options in relation to the manufacturing operation. We arecurrently considering several offshore manufacturing facilities and following regulatory approvals, we expect sales and distribution to commence in 2008-09,"​ he said. Each year, malaria causes over 500m acute illnesses and one to two million deaths - primarily in small children - and 90 per cent of the burden of disease is in Africa, however, traditional anti-malaria tablets are in many cases ineffective in the treatment of children suffering from malnutrition and diarrhea. Proto-Pharma claims its drug uses a new method of administration and a formula that offers a number of significant advantages over current tablet style medications. "Particularly effective in children, the treatment attacks the malaria parasite at far greater speed than the conventional tablets, reducing the need for continued hospitalisation and resulting in significant cost savings to Governments and relief organisations,"​ the company said. This latest manufacturing deal follows a contract signed in December between Eastland's subsidiary Eastland Medical Systems South Africa (EMSSA) and Botswana firm Star Medical, which grants EMSSA the exclusive distribution of the new treatment in Sub-Saharan Africa. "These two deals are expected to generate combined direct revenues of up to $40m in the second year of production, increasing to $80m by Year 4 as the treatment increasingly gains market and Aid subsidiary support,"​ said Patterson. "Eastland has now secured access to approximately 97 per cent of the world's malaria infected countries and their combined 485m reported cases of malaria."

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

PBPK modeling that saves you time and money

PBPK modeling that saves you time and money

Content provided by Lonza Small Molecules | 09-Oct-2023 | White Paper

Understanding pharmacokinetic behaviors ahead of later-stage development means making informed decisions earlier. This enhanced capability helps your drug...

Related suppliers

Follow us

Products

View more

Webinars